 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...

ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development

YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...

ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370

YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...

ContraFect to Present at the World Anti-Microbial Resistance Congress 2023

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on ContraFect (CFRX Research Report), with a price target... In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on ContraFect (CFRX &#8211...

ContraFect (CFRX) Receives a Buy from Maxim Group

YONKERS, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...

ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update

YONKERS, N.Y., June 27, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides as new medical modalities for the treatment of life-threatening...

ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million

Sientra, ContraFect top healthcare gainers; Elevation, Longboard among losers

YONKERS, N.Y., June 08, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening...

ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023

YONKERS, N.Y., May 15, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening...

ContraFect Reports First Quarter 2023 Financial Results and Provides Business Update

Contrafect GAAP EPS of -$0.69

ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins, and Amurin Peptides. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.

Watchers	9,883
52-Wk Low	$0.51
52-Wk High	$15.76

Market Cap	$6.21M
Volume (M)	7,119.00
52-Wk High	$15.76
52-Wk Low	$0.51

CFRX ContraFect Corp

About

Feed

News

Fundamentals